Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk
- 1 January 2004
- journal article
- clinical trial
- Published by Elsevier in Thrombosis Research
- Vol. 114 (2) , 143-148
- https://doi.org/10.1016/j.thromres.2004.06.005
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Platelet-Mediated Modulation of Adaptive ImmunityImmunity, 2003
- Soluble CD40 Ligand in Acute Coronary SyndromesNew England Journal of Medicine, 2003
- CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanismNature Medicine, 2002
- Requirement for CD154 in the progression of atherosclerosisNature Medicine, 1999
- Reduction of atherosclerosis in mice by inhibition of CD40 signallingNature, 1998
- Help for cytotoxic-T-cell responses is mediated by CD40 signallingNature, 1998
- T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactionsNature, 1998
- CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cellsNature, 1998
- The Role of CD40 Ligand in Costimulation and T‐Cell ActivationImmunological Reviews, 1996
- Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgMNature, 1993